COMPLEX SCIENCE
BETTER BY DESIGN.
DE-RISKING PRODUCT DEVELOPMENT AND SHORTENING TIME TO MARKET
Advance New Drug Candidates: Stuck in early development? Our proprietary platform enables high-performance oral formulations of poorly soluble APIs—boosting bioavailability, accelerating development, and unlocking therapeutic potential.
​
Reformulate Generics for Competitive Advantage: Transform existing molecules into next-gen oral formulations. Improve PK profiles, reduce dose variability, and differentiate your product in the generic market.
​
Support for Preclinical Toxicology: Ensure relevant systemic exposure in early-stage studies. Our platform allows for effective formulation for toxicity profiling of the drug candidate—helping you generate meaningful data and move faster through development.
2018
Year Established
12+
Substances Tested
4
Number of Publications
4
Patents Granted
TECHNOLOGY
Dry powder formulation
-
Enables drug loading without the use of solvents
-
Eliminates the need for rotary evaporation, spray-drying, or freeze-drying
-
Solid dispersion achieved without thermoplastic polymers
-
Offers excellent physical and chemical stability
Direct Compression into Tablets
-
Utilizes excipient that serves as both a carrier and a binder
-
Avoids the complexity of soft gel capsule formulation for poorly soluble drugs
-
Removes the need to create salt conjugates or co-crystals
Scalable and Efficient Manufacturing
-
Compatible with standard, widely available industrial equipment
-
Requires only a minimal number of processing steps
-
Operates with a small industrial footprint
-
Supports sustainable and responsible production practices
ABOUT US
VELTIO PHARMA AB is an innovative pharmaceutical company that aspires to transform problem poorly soluble drugs into bestselling products with high bioavailability. Through our proprietary nanotechnology platform, we aim to improve the solid oral dosage forms that make difference to the patients. Our special focus therapeutic areas include pain and inflammation, immune disorders, and cancer.
We offer in-licensing opportunities and services in pre-clinical to Phase I/IIa solid oral dosage form development pertaining to our technology.
KEY MANAGEMENT TEAM
ALBERT MIHRANYAN, PhD
Founder
DANIEL BERGSTRÖM, PhD
Chairman of the Board
STINA LUNDGREN, PhD
Chief Executive Officer
